Trial Profile
A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer - (IM-BATTLE-2 Program)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms IM-BATTLE-2
- 18 Aug 2023 Planned End Date changed from 30 Sep 2024 to 31 Dec 2024.
- 18 Aug 2023 Planned primary completion date changed from 30 Sep 2023 to 31 Dec 2024.
- 05 Jul 2022 Planned End Date changed from 30 Sep 2021 to 30 Sep 2024.